EN – ESPERITE financial results for 2014 published, metamorphosis completed, first positive forecast growth at €36mio Revenues (+30%) for 2015

March 17, 2015 Financial Reports , Group News
esperite_financial _summary_2014_teaser

ESPERITE (“Esperite N.V. (Euronext: ESP, “ESPERITE” or “the Company”) strengthens market position of Genoma with acquisitions of exclusive technologies for fully-certified groundbreaking genetic tests.

Stem cell historical CryoSave’s core business now profitable and improving.

Consolidated operations, headcount rationalization, integrated sales and marketing strategies, laboratories integration and processes automatization completed to yield enhanced performance and results.

Zutphen, The Netherlands – 17 March 2015

read more

FR – Publication des résultats financiers 2014 de ESPERITE, métamorphose terminée, première prévision de croissance positive des revenus à 36 millions € (+30%) pour 2015

March 17, 2015 Financial Reports , Group News

ESPERITE (Esperite NV, (Euronext : ESP) « Esperite » ou « la Société ») renforce le positionnement de Genoma sur le marché par des acquisitions de technologies exclusives pour la réalisation de tests génétiques révolutionnaires entièrement certifiés.

Le coeur de métier historique de CryoSave dans les cellules souches est maintenant rentable et en constante amélioration.

Opérations consolidées, effectifs rationalisés, stratégies vente et marketing alignées, laboratoires intégrés, et processus automatisés pour l’obtention de meilleures performances et résultats.

Zutphen, Hollande – 17 Mars 2015

read more

Cryo-Save Group N.V.: positive outcome for Cryo-Save in legal proceedings against Salveo: EGM 9 September 2013 postponed

September 6, 2013 Group News
Tags
,

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces that the extraordinary general meeting of shareholders (“EGM”) scheduled for 9 September 2013, that was convened by the company’s minority shareholder Salveo Holding S.A. (“Salveo”) in breach of the 180-day response time that Cryo-Save’s board of directors invoked, has been adjourned by court order.

read more

Salveo breaches response time and convenes EGM

July 26, 2013 Group News

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces today that it has taken notice of the fact that Salveo Holding S.A. (‘Salveo’), the company’s minority shareholder with 27%, has convened an extraordinary general meeting of shareholders (‘EGM’) that shall be proposed to resolve on the appointment of a new executive director (CEO) and the replacement of one non-executive director.

read more

Presentation of proposition and invocation response time

June 3, 2013 Group News

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces today that it has been presented with the outlines of the proposition of Salveo Holding S.A (‘Salveo’), the company’s major shareholder, underlying its request to convene an extraordinary general meeting of shareholders (‘EGM’) that shall be proposed to resolve on the appointment of a new CEO and the replacement of one non-executive director.

read more

Update of Matters Salveo

May 30, 2013 Group News
Tags

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces further to its press release dated 15 May and as a matter of update of matters regarding Salveo Holding S.A. (‘Salveo’), Cryo-Save’s new 27 % shareholder, that it has received a request by Salveo to convene an extraordinary general meeting of shareholders.

read more

AGM resolutions

May 15, 2013 Group News

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces that all proposed resolutions at today’s AGM were passed, except for the proposal to cancel the shares currently held in treasury.

read more

Director shareholding – Block-trades

May 10, 2013 Group News

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, has been informed that via a block-trade Mr Johan Goossens, Chairman, sold 900,000 ordinary shares of Euro 0.10 (‘Ordinary Shares’) to Salveo Holding SA on 7 May 2013 and that at the same day Mr Marc Waeterschoot, co-founder and former Board Member of Cryo-Save, via a block-trade sold 1,460,000 Ordinary Shares to Salveo Holding SA, both at a price of €1.70. Salveo Holding SA has not contacted management of Cryo-Save about its intentions as a major shareholder.

read more